SCHEMBL8092638

SCHEMBL8092638

O=C(O)c1cccc2c1-c1ccccc1C2CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.50
ALDH1A1 P00352 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
MYC P01106 1/20 0.45
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
GFER P55789 1/20 0.43
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.41
FABP5 Q01469 3/20 0.40
FABP7 O15540 2/20 0.40
KDM4E B2RXH2 2/20 0.39
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27583741 0.87 KEAP1 (0.49) HNF4AALDH1A1LMNAMAPTKMT2A
SCHEMBL4624902 0.83 ALDH1A1 (0.39) HNF4AALDH1A1L3MBTL1MAPTKMT2A
SCHEMBL10085227 0.83 ALDH1A1 (0.45) HNF4AALDH1A1L3MBTL1LMNAMAPT
SCHEMBL22166256 0.82 ALDH1A1 (0.38) HNF4AALDH1A1L3MBTL1LMNAMAPT
SCHEMBL28482428 0.82 HNF4A (0.45) HNF4AALDH1A1L3MBTL1LMNAMAPT
SCHEMBL8399565 0.81 FABP5 (0.39) ALDH1A1L3MBTL1LMNAKMT2AFABP5
SCHEMBL1934919 0.80 ALDH1A1 (0.43) HNF4AALDH1A1L3MBTL1LMNAMAPT
SCHEMBL7724549 0.79 ALDH1A1 (0.45) HNF4AALDH1A1L3MBTL1LMNAMAPT
SCHEMBL16253851 0.77 KMT2A (0.51) ALDH1A1L3MBTL1LMNAMAPTMYC
SCHEMBL3062707 0.77 HTR2A (0.47) MAPTKMT2AFABP5FABP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11406618-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2022-08-09 US disclosed
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2019-05-16 US disclosed
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2019-05-16 US disclosed
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2019-03-05 US disclosed
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2019-03-05 US disclosed
EP-2654797-B1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2017-11-08 EP disclosed
EP-2654797-B1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2017-11-08 EP disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
EP-2654797-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES Nektar Therapeutics (US) 2013-10-30 EP disclosed
WO-2012088522-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2012-06-28 WO disclosed
US-6046306-A SOLID PHASE SYNTHESIS OF PEPTIDE NUCLEIC ACIDS ALLOWING OLIGOMER TO BE CLEAVED OFF FROM THE SOLID SUPPORT UNDER THE ALKALINE CONDITIONS CONVENTIONALLY USED FOR OLIGONUCLEOTIDES HOECHST AKTIENGESELLSCHAFT (DE) 2000-04-04 US disclosed
EP-0672700-B1 PNA-synthesis using an aminoprotecting group which is labile against weak acids HOECHST AG (DE) 1999-06-02 EP disclosed
EP-0672700-A1 PNA-synthesis using an aminoprotecting group which is labile against weak acids HOECHST AKTIENGESELLSCHAFT (DE) 1995-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates KDR, FLT4, FLT1 HNF4A 3345/4885ALDH1A1 3041/4885L3MBTL1 3148/4885
US-11406618-B2 Polymer-des-ethyl sunitinib conjugates KDR, FLT4, FLT1 HNF4A 3345/4885ALDH1A1 3041/4885L3MBTL1 3148/4885
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES KDR, FLT4, FLT1 HNF4A 3345/4885ALDH1A1 3041/4885L3MBTL1 3148/4885
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES KDR, FLT4, FLT1 HNF4A 3345/4885ALDH1A1 3041/4885L3MBTL1 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.